These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 35667964)

  • 41. Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases.
    Prattichizzo F; La Sala L; Rydén L; Marx N; Ferrini M; Valensi P; Ceriello A
    Eur J Prev Cardiol; 2019 Dec; 26(2_suppl):73-80. PubMed ID: 31766918
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [SGLT2 inhibitor or GLP-1 receptor agonist in a type 2 diabetic patient with cardiovascular disease ?].
    Scheen AJ; Paquot N
    Rev Med Suisse; 2018 Aug; 14(615):1460-1465. PubMed ID: 30136462
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of glucagon-like peptide 1 receptor agonists and sodium-glucose transport protein 2 inhibitors on blood pressure and lipid profile.
    Muzurović E; Mikhailidis DP
    Expert Opin Pharmacother; 2020 Dec; 21(17):2125-2135. PubMed ID: 32697112
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Combination therapy with SGLT2 inhibitor and GLP-1 receptor agonist in type 2 diabetes].
    Scheen AJ
    Rev Med Suisse; 2019 Aug; 15(659):1436-1441. PubMed ID: 31436058
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of CVOTs in primary and secondary prevention of kidney disease.
    De Cosmo S; Viazzi F; Piscitelli P; Leoncini G; Mirijello A; Bonino B; Pontremoli R
    Diabetes Res Clin Pract; 2019 Nov; 157():107907. PubMed ID: 31676332
    [TBL] [Abstract][Full Text] [Related]  

  • 46. For Patients with Type 2 Diabetes Mellitus Who Are Taking a GLP-1 Receptor Agonist, an SGLT2 Inhibitor May Be Preferred to a Sulfonylurea as Add-on Therapy.
    Ebell MH
    Am Fam Physician; 2021 Oct; 104(4):424. PubMed ID: 34652104
    [No Abstract]   [Full Text] [Related]  

  • 47. Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns.
    Lim S; Kim KM; Nauck MA
    Trends Endocrinol Metab; 2018 Apr; 29(4):238-248. PubMed ID: 29463450
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis.
    D'Andrea E; Kesselheim AS; Franklin JM; Jung EH; Hey SP; Patorno E
    Cardiovasc Diabetol; 2020 Sep; 19(1):154. PubMed ID: 32993654
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection.
    Sridhar VS; Dubrofsky L; Boulet J; Cherney DZ
    J Bras Nefrol; 2020; 42(4):467-477. PubMed ID: 32926067
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress.
    Luna-Marco C; Iannantuoni F; Hermo-Argibay A; Devos D; Salazar JD; Víctor VM; Rovira-Llopis S
    Free Radic Biol Med; 2024 Mar; 213():19-35. PubMed ID: 38220031
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease.
    Dougherty JA; Guirguis E; Thornby KA
    Ann Pharmacother; 2021 Jan; 55(1):65-79. PubMed ID: 32571083
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists.
    Scheen AJ
    Diabetes Res Clin Pract; 2018 Sep; 143():88-100. PubMed ID: 29944969
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis.
    Global Health & Population Project on Access to Care for Cardiometabolic Diseases (HPACC)
    Lancet Diabetes Endocrinol; 2021 Dec; 9(12):825-836. PubMed ID: 34656210
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review.
    Mantovani A; Byrne CD; Targher G
    Lancet Gastroenterol Hepatol; 2022 Apr; 7(4):367-378. PubMed ID: 35030323
    [TBL] [Abstract][Full Text] [Related]  

  • 55. GLP-1 Receptor Agonists and SGLT-2 Inhibitors as Adjuncts to Insulin in Type 1 Diabetes: Benefits and Concerns.
    Dimitriadis GD; Lambadiari V
    J Clin Endocrinol Metab; 2023 Mar; 108(4):e52-e53. PubMed ID: 36507904
    [No Abstract]   [Full Text] [Related]  

  • 56. Comparing medication persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists in real-world setting.
    Rea F; Ciardullo S; Savaré L; Perseghin G; Corrao G
    Diabetes Res Clin Pract; 2021 Oct; 180():109035. PubMed ID: 34487757
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients.
    Uneda K; Kawai Y; Yamada T; Kinguchi S; Azushima K; Kanaoka T; Toya Y; Wakui H; Tamura K
    Sci Rep; 2021 May; 11(1):10166. PubMed ID: 33986377
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The combination of GLP-1 analogs and SGLT2 inhibitors : new perspectives ?].
    Ritz C; Jaafar J; Philippe J
    Rev Med Suisse; 2017 May; 13(565):1134-1139. PubMed ID: 28639755
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of diabetes mellitus has borne much fruit in the prevention of cardiovascular disease.
    Yagyu H; Shimano H
    J Diabetes Investig; 2022 Sep; 13(9):1472-1488. PubMed ID: 35638331
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Indications of antidiabetic drugs beyond glucose control].
    Hartmann NK; Lehrke M
    MMW Fortschr Med; 2023 Mar; 165(5):42-49. PubMed ID: 36894856
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.